瀛晟科學(00209.HK):王敬渝獲委任為執行董事及董事會主席
格隆匯9月3日丨瀛晟科學(00209.HK)公吿,董事會謹此宣佈:1.李忠海於2025年9月3日透過Hurray Talent(一間由李忠海全資擁有公司)出售總數為37,392,913股公司股份(相當於公司已發行股本約24.16%)予Peak Access(一間由王全資擁有公司)。出售事項完成後,公司主要股東由Hurray Talent變更為Peak Access;2.李忠海辭任公司執行董事,自2025年9月3日起生效;3.蔣青輝辭任公司執行董事及董事會主席,亦不再為提名委員會主席,自2025年9月3日起生效;4.王敬渝已獲委任為公司執行董事及董事會主席,自2025年9月3日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.